Neal M. Dixit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Neal M. Dixit has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Boback Ziaeian
David Geffen School of Medicine at UCLA
3 shared publications - Gregg Fonarow
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
3 shared publications - Saul Schaefer
Internal Medicine, Division of Cardiovascular Medicine, UC Davis Health, Sacramento, USA
2 shared publications Ali Nsair
Department of Medicine David Geffen School of Medicine at UCLA Los Angeles California USA
1 shared publication- Ali Nsair
Division of Cardiology University of California, Los Angeles Los Angeles, CA United States
1 shared publication David Li
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
1 shared publication
Latest Publications
- 1 January 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (1) , e012530
Is It Primetime for Finerenone in Heart Failure?
- 1 January 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (1) , e012530
Is It Primetime for Finerenone in Heart Failure?
- Open Access
- 14 August 2024
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 19, 100723
Will DANCAVAS be the most important screening trial in the last 50 years?
- 14 August 2024
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 19, 100723
Open AccessWill DANCAVAS be the most important screening trial in the last 50 years?
- Open Access
- 1 May 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (7) , 1226-1237
Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
- 1 May 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (7) , 1226-1237
Open AccessCost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
- 1 March 2023
- Published by Elsevier in JACC: Heart Failure
- Vol. 11 (5) , 541-551
Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction
- 1 March 2023
- Published by Elsevier in JACC: Heart Failure
- Vol. 11 (5) , 541-551
Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction
- Open Access
- 1 March 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (2) , 575-579.e2
Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital
- 1 March 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (2) , 575-579.e2
Open AccessIntegration of clinical pharmacists into a heart failure clinic within a safety-net hospital
- Open Access
- 23 April 2021
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 15
Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
Heart failure remains a huge societal concern despite medical advancement, with an annual direct cost of over $30 billion. While guideline-directed medical therapy (GDMT) is proven to reduce morbidity and mortality, many eligible patients with heart failure with reduced ejection fraction (HFrEF) are not receiving one or more of the recommended medications, often due to suboptimal initiation and titration in the outpatient setting. Hospitalization serves as a key point to initiate and titrate GDMT. Four evidence-based therapies have clinical benefit within 30 days of initiation and form a crucial foundation for HFrEF therapy: renin-angiotensin-aldosterone system inhibitors with or without a neprilysin inhibitor, β-blockers, mineralocorticoid-receptor-antagonists, and sodium-glucose cotransporter-2 inhibitors. The authors present a practical guide for the implementation of these four pillars of GDMT during a hospitalization for acute heart failure.
- 23 April 2021
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 15
Open AccessOptimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
Heart failure remains a huge societal concern despite medical advancement, with an annual direct cost of over $30 billion. While guideline-directed medical therapy (GDMT) is proven to reduce morbidity and mortality, many eligible patients with heart failure with reduced ejection fraction (HFrEF) are not receiving one or more of the recommended medications, often due to suboptimal initiation and titration in the outpatient setting. Hospitalization serves as a key point to initiate and titrate GDMT. Four evidence-based therapies have clinical benefit within 30 days of initiation and form a crucial foundation for HFrEF therapy: renin-angiotensin-aldosterone system inhibitors with or without a neprilysin inhibitor, β-blockers, mineralocorticoid-receptor-antagonists, and sodium-glucose cotransporter-2 inhibitors. The authors present a practical guide for the implementation of these four pillars of GDMT during a hospitalization for acute heart failure.
- Open Access
- 27 March 2021
- Published by Wiley in Clinical Cardiology
- Vol. 44 (5) , 596-598
Should SGLT2i be used prior to transcatheter edge‐to‐edge repair for secondary mitral regurgitation?
- 27 March 2021
- Published by Wiley in Clinical Cardiology
- Vol. 44 (5) , 596-598
Open AccessShould SGLT2i be used prior to transcatheter edge‐to‐edge repair for secondary mitral regurgitation?
- 9 October 2020
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 21, e926206-1-e926206-4
Use of the 1,3-β-D-Glucan Assay for the Early Detection of Fungal Endocarditis in a 45-Year-Old Man
Patient: Male, 45-year- old Final Diagnosis: Fungal endocarditis Symptoms: Cough center dot fever center dot hemiplegia center dot malaise center dot shortness of breath Medication: - Clinical Procedure: Endarterectomy center dot valve replacement surgery Specialty: Cardiology Objective: Challenging differential diagnosis Background: The management of fungal endocarditis is difficult due to high mortality and incidence of embolization. Fungal blood cultures are the criterion standard for diagnosis but show slow growth or remain negative in more than 50% of cases. We present a case in which the 1,3-b-D-glucan (BG) assay was used to initiate antifungal treatment prior to growth in blood culture. Case Report: A 45-year-old man with known intravenous drug use presented to the Emergency Department in acute hypoxemic respiratory failure with a prominent aortic regurgitation murmur. Imaging findings were suggestive of endocarditis. In the Intensive Care Unit, investigations confirmed aortic valve infective endocarditis with abscess. Evidence of widespread embolization, including a shin abscess positive for Candida albicans combined with a positive BG assay prompted treatment with antifungal medication prior to positive fungal cultures. The patient underwent valve replacement and during recovery was incidentally found to have subclinical cerebral infarctions caused by a septic thrombus positive for C. albicans in the right carotid artery despite weeks of antifungal treatment. Carotid endarterectomy successfully removed the thrombus, but the patient developed a rightsided stroke. Four months later, the patient has no evidence of aortic insufficiency on echocardiogram and has made a nearly full recovery from the stroke. Conclusions: We report a case of left-sided fungal endocarditis in which the BG assay was used for timely medical and surgical management leading to a successful cardiac outcome. Stroke from septic emboli is a potential complication even after weeks of antifungal therapy and valvular replacement.
- 9 October 2020
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 21, e926206-1-e926206-4
Use of the 1,3-β-D-Glucan Assay for the Early Detection of Fungal Endocarditis in a 45-Year-Old Man
Patient: Male, 45-year- old Final Diagnosis: Fungal endocarditis Symptoms: Cough center dot fever center dot hemiplegia center dot malaise center dot shortness of breath Medication: - Clinical Procedure: Endarterectomy center dot valve replacement surgery Specialty: Cardiology Objective: Challenging differential diagnosis Background: The management of fungal endocarditis is difficult due to high mortality and incidence of embolization. Fungal blood cultures are the criterion standard for diagnosis but show slow growth or remain negative in more than 50% of cases. We present a case in which the 1,3-b-D-glucan (BG) assay was used to initiate antifungal treatment prior to growth in blood culture. Case Report: A 45-year-old man with known intravenous drug use presented to the Emergency Department in acute hypoxemic respiratory failure with a prominent aortic regurgitation murmur. Imaging findings were suggestive of endocarditis. In the Intensive Care Unit, investigations confirmed aortic valve infective endocarditis with abscess. Evidence of widespread embolization, including a shin abscess positive for Candida albicans combined with a positive BG assay prompted treatment with antifungal medication prior to positive fungal cultures. The patient underwent valve replacement and during recovery was incidentally found to have subclinical cerebral infarctions caused by a septic thrombus positive for C. albicans in the right carotid artery despite weeks of antifungal treatment. Carotid endarterectomy successfully removed the thrombus, but the patient developed a rightsided stroke. Four months later, the patient has no evidence of aortic insufficiency on echocardiogram and has made a nearly full recovery from the stroke. Conclusions: We report a case of left-sided fungal endocarditis in which the BG assay was used for timely medical and surgical management leading to a successful cardiac outcome. Stroke from septic emboli is a potential complication even after weeks of antifungal therapy and valvular replacement.
- Open Access
- 28 August 2020
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 4 (10) , bvaa130
Sudden Cardiac Arrest in a Patient With Myxedema Coma and COVID-19
SARS-CoV-2 infection is associated with significant lung and cardiac morbidity but there is a limited understanding of the endocrine manifestations of coronavirus disease 2019 (COVID-19). Although thyrotoxicosis due to subacute thyroiditis has been reported in COVID-19, it is unknown whether SARS-CoV-2 infection can also lead to decompensated hypothyroidism. We present the first case of myxedema coma (MC) in COVID-19 and we discuss how SARS-CoV-2 may have precipitated multiorgan damage and sudden cardiac arrest in our patient. A 69-year-old woman with a history of small cell lung cancer presented with hypothermia, hypotension, decreased respiratory rate, and a Glasgow Coma Scale score of 5. The patient was intubated and administered vasopressors. Laboratory investigation showed elevated thyrotropin, very low free thyroxine, elevated thyroid peroxidase antibody, and markedly elevated inflammatory markers. SARS-CoV-2 test was positive. Computed tomography showed pulmonary embolism and peripheral ground-glass opacities in the lungs. The patient was diagnosed with myxedema coma with concomitant COVID-19. While treatment with intravenous hydrocortisone and levothyroxine were begun the patient developed a junctional escape rhythm. Eight minutes later, the patient became pulseless and was eventually resuscitated. Echocardiogram following the arrest showed evidence of right heart dysfunction. She died 2 days later of multiorgan failure. This is the first report of SARS-CoV-2 infection with MC. Sudden cardiac arrest likely resulted from the presence of viral pneumonia, cardiac arrhythmia, pulmonary emboli, and MC—all of which were associated with the patient’s SARS-CoV-2 infection.
- 28 August 2020
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 4 (10) , bvaa130
Open AccessSudden Cardiac Arrest in a Patient With Myxedema Coma and COVID-19
SARS-CoV-2 infection is associated with significant lung and cardiac morbidity but there is a limited understanding of the endocrine manifestations of coronavirus disease 2019 (COVID-19). Although thyrotoxicosis due to subacute thyroiditis has been reported in COVID-19, it is unknown whether SARS-CoV-2 infection can also lead to decompensated hypothyroidism. We present the first case of myxedema coma (MC) in COVID-19 and we discuss how SARS-CoV-2 may have precipitated multiorgan damage and sudden cardiac arrest in our patient. A 69-year-old woman with a history of small cell lung cancer presented with hypothermia, hypotension, decreased respiratory rate, and a Glasgow Coma Scale score of 5. The patient was intubated and administered vasopressors. Laboratory investigation showed elevated thyrotropin, very low free thyroxine, elevated thyroid peroxidase antibody, and markedly elevated inflammatory markers. SARS-CoV-2 test was positive. Computed tomography showed pulmonary embolism and peripheral ground-glass opacities in the lungs. The patient was diagnosed with myxedema coma with concomitant COVID-19. While treatment with intravenous hydrocortisone and levothyroxine were begun the patient developed a junctional escape rhythm. Eight minutes later, the patient became pulseless and was eventually resuscitated. Echocardiogram following the arrest showed evidence of right heart dysfunction. She died 2 days later of multiorgan failure. This is the first report of SARS-CoV-2 infection with MC. Sudden cardiac arrest likely resulted from the presence of viral pneumonia, cardiac arrhythmia, pulmonary emboli, and MC—all of which were associated with the patient’s SARS-CoV-2 infection.